Tesamorelin vs CJC-1295: two GHRH analogues, two different design strategies
Tesamorelin and CJC-1295 are the two best-characterised synthetic GHRH analogues in research-peptide use. They were engineered to solve the same problem — native GHRH circulates for only minutes before dipeptidyl-peptidase-IV (DPP-IV) inactivates it — but they solve it in opposite ways. The choice between them in a research protocol depends on whether the question is about acute pulsatile GH signalling or about sustained multi-day elevation of the somatotropic axis.
Two engineering strategies for the same problem
Native GHRH is a 44-amino-acid peptide that the hypothalamus releases in pulses lasting minutes. It binds the pituitary GHRH receptor (GHRH-R), triggers cAMP-mediated growth-hormone release from somatotroph cells, and is then rapidly inactivated by DPP-IV cleavage of its N-terminal dipeptide. The plasma half-life is approximately three to seven minutes.
For a research peptide to be useful, this half-life has to be extended. Tesamorelin and CJC-1295 take entirely different approaches:
- Tesamorelin — block the cleavage site. The first 44 residues of native GHRH are retained; the N-terminal tyrosine is replaced with a trans-3-hexenoyl modification that physically obstructs DPP-IV access. Binding affinity at the GHRH receptor is preserved. Plasma half-life extends to roughly 26-38 minutes. Pulsatile GH release pattern is preserved.
- CJC-1295 (with DAC) — anchor the peptide to plasma albumin. The GHRH (1-29) active fragment is modified with a maleimidopropionyl-lysine linker that covalently binds the free thiol on cysteine-34 of circulating albumin. The complex is too large for renal clearance; effective half-life extends to approximately 8 days. Downstream signalling is sustained rather than pulsatile.
- CJC-1295 without DAC — a different molecule entirely. The “no-DAC” variant (often called Modified GRF 1-29) lacks the albumin-binding linker. Half-life is intermediate — about 30 minutes — and the molecule behaves more like Tesamorelin than like CJC-1295 with DAC. The naming confusion is widespread in the research community; the no-DAC variant is a distinct compound.
Receptor binding — both target GHRH-R
At the pituitary receptor level, Tesamorelin and CJC-1295 are indistinguishable. Both are full agonists at GHRH-R. Both produce cAMP elevation and GH release with EC50 values in the low-nanomolar range. The receptor pharmacology does not separate them.
The downstream effects diverge because of pharmacokinetics. With Tesamorelin, plasma concentration falls below the receptor-binding threshold within an hour or two of injection; subsequent GH release follows the natural pulsatile pattern between doses. With CJC-1295 + DAC, plasma concentration remains at receptor-activating levels for days; the natural pulsatile pattern is partially overridden by sustained signalling.
Honest take: if a research protocol needs to preserve the natural GH pulse, Tesamorelin is the closer mimic of physiological GHRH signalling. If the protocol needs sustained elevation across multiple days with infrequent dosing, CJC-1295 with DAC is the engineered choice. They are not interchangeable.
IGF-1 kinetics — different dose-response curves
Both peptides elevate plasma IGF-1 over a multi-day timecourse following the GH release they trigger. The shape of the IGF-1 curve differs:
- Tesamorelin. Daily subcutaneous administration produces a stepwise IGF-1 elevation that plateaus over 1-2 weeks at approximately the upper end of the age-adjusted normal range. The plateau is maintained as long as dosing continues; discontinuation returns IGF-1 to baseline within 2-3 weeks. The phase-3 trials in HIV-associated lipodystrophy patients are the source of most of this kinetic data [1].
- CJC-1295 with DAC. Once-weekly administration produces a sustained IGF-1 elevation that builds across several weeks of dosing. Peak elevation tends to be higher than Tesamorelin at equivalent total weekly dose. The published phase-1 data shows IGF-1 elevation persists for ~30 days after a single dose [2].
Visceral-adipose depot selectivity
The clinical-development question Tesamorelin was built to answer is whether GHRH-axis activation selectively reduces visceral adipose tissue (VAT) while sparing subcutaneous adipose. Two phase-3 randomised controlled trials in HIV-associated lipodystrophy patients established that effect — approximately 15-18% VAT reduction over 26 weeks of daily subcutaneous administration [1].
CJC-1295 with DAC has been studied for visceral-adipose research but with substantially less clinical-trial depth. The molecule has been investigated in earlier-stage human pharmacology studies but did not advance through a phase-3 development program comparable to Tesamorelin’s. The depot-selectivity question with CJC-1295 + DAC is therefore answered with less certainty in the published literature.
Side-by-side research summary
UAE research-supply considerations
Both molecules are available in the UAE as lyophilised research-grade powder. For Tesamorelin, the most common vial format is 10 mg; for CJC-1295 with DAC, 2-5 mg is typical. Wellness Labs supplies both. The reconstitution and storage protocols overlap (bacteriostatic water, refrigerated re-entry, ~28-day post-reconstitution window) — covered in our storage and reconstitution guide.
Quality verification differs between the two: Tesamorelin’s lipid modification is detectable by mass-spectrometry as a +H+ ion at ~5,136 Da; CJC-1295 with DAC’s maleimide linker is similarly mass-detectable. Both should ship with HPLC purity ≥98% and mass-spec confirmation of the modification on every batch. The Tesamorelin parent overview covers the analytical-verification framework in more depth.
Open research questions in the comparison
- Whether the depot-selectivity effect Tesamorelin demonstrates for visceral adipose extends to CJC-1295 + DAC at equivalent total GHRH signalling. The sustained vs pulsatile mechanism may matter at the adipose-tissue receptor level.
- Long-term safety comparisons. Tesamorelin has multi-year observational follow-up from the regulatory-approved indication; CJC-1295 + DAC has more limited long-term safety data.
- Whether a longer-acting Tesamorelin analogue (combining DPP-IV resistance with albumin binding) would outperform either current molecule. The pharmacology suggests it should, but no such molecule has reached clinical development.
Further reading
- [1] Spooner & Olin — Ann Pharmacother 2012. Tesamorelin: a growth-hormone-releasing factor analogue for HIV-associated lipodystrophy.
- [2] Teichman et al. — J Clin Endocrinol Metab 2006. Pharmacokinetics, pharmacodynamics, and tolerability of CJC-1295 — the phase-1 albumin-bound GHRH analogue study.
- Tesamorelin — parent overview. Mechanism, regulatory history, supply landscape.
- CJC-1295 + Ipamorelin research overview. The most common research stacking pair.
- Tesamorelin vs the wider GHRH-analogue class. Sermorelin, Tesamorelin, and Modified GRF (1-29).
Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.
Frequently asked questions
- What is the main difference between Tesamorelin and CJC-1295?
- Both bind the same pituitary GHRH receptor with comparable affinity. The difference is plasma half-life: Tesamorelin extends native GHRH from ~5 minutes to ~30 minutes via an N-terminal lipid modification that blocks DPP-IV cleavage, preserving pulsatile GH release. CJC-1295 with DAC extends half-life to roughly 8 days by covalently binding plasma albumin, producing sustained rather than pulsatile signalling. The dosing frequencies that result (daily vs weekly) reflect the underlying pharmacokinetic engineering.
- Does Tesamorelin produce a stronger IGF-1 response than CJC-1295?
- No — CJC-1295 with DAC produces a higher peak IGF-1 elevation at equivalent total weekly dose because of the sustained receptor activation. Tesamorelin produces a stepwise IGF-1 elevation that plateaus in the upper-normal range; CJC-1295 with DAC produces a sustained elevation that builds across several weeks. The clinical-research significance of the difference depends on whether the research question concerns acute pulsatile signalling or chronic axis elevation.
- Which is more studied — Tesamorelin or CJC-1295?
- Tesamorelin has substantially more clinical-trial validation. Two phase-3 randomised controlled trials and a 2014 NAFLD-extension RCT, plus multi-year observational follow-up, establish the visceral-adipose efficacy and safety profile. CJC-1295 with DAC has published phase-1 pharmacokinetic studies and several phase-2 trials in different research contexts but did not advance through a comparable phase-3 program. Tesamorelin received FDA approval in 2010 for a specific indication; CJC-1295 with DAC remains a research compound.
- Is CJC-1295 without DAC the same as Modified GRF (1-29)?
- Yes — these are two names for the same molecule. Modified GRF (1-29) is the 29-residue GHRH active fragment with four amino-acid substitutions (Tyr1 → D-Ala, Ala8 → Gln, Leu27 → Gln27, Arg28 → Ser) that block DPP-IV cleavage. The "CJC-1295 without DAC" naming is widespread in research-community usage but technically refers to the same Modified GRF (1-29) molecule. Plasma half-life is ~30 minutes, similar to Tesamorelin's.
- Can Tesamorelin and CJC-1295 be combined?
- There is no published research-protocol data combining Tesamorelin and CJC-1295. Both bind the same GHRH receptor — combining them would not produce additive signalling beyond receptor saturation. The combination researchers do study is GHRH analogue + ghrelin-mimetic (most commonly CJC-1295 + Ipamorelin, occasionally Tesamorelin + Ipamorelin), because the two pathways act through distinct receptors and produce complementary effects.
- Which is preferred for visceral-adipose research in the UAE?
- Tesamorelin is the molecule with phase-3 validated visceral-adipose tissue research data and the FDA approval for a related indication. For visceral-adipose research questions specifically, Tesamorelin is the molecule with the strongest published evidence base. Wellness Labs supplies Tesamorelin as research-grade 10 mg lyophilised vials with HPLC CoA per batch.